NO20050429L - Substituert kinolin-CCR5-reseptorantagonister - Google Patents
Substituert kinolin-CCR5-reseptorantagonisterInfo
- Publication number
- NO20050429L NO20050429L NO20050429A NO20050429A NO20050429L NO 20050429 L NO20050429 L NO 20050429L NO 20050429 A NO20050429 A NO 20050429A NO 20050429 A NO20050429 A NO 20050429A NO 20050429 L NO20050429 L NO 20050429L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- ccr5 receptor
- substituted quinoline
- ccr5
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45168702P | 2002-06-27 | 2002-06-27 | |
PCT/US2003/020950 WO2004002960A1 (en) | 2002-06-27 | 2003-06-24 | Substituted quinoline ccr5 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20050429D0 NO20050429D0 (no) | 2005-01-26 |
NO20050429L true NO20050429L (no) | 2005-03-29 |
Family
ID=30001033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050429A NO20050429L (no) | 2002-06-27 | 2005-01-26 | Substituert kinolin-CCR5-reseptorantagonister |
Country Status (17)
Country | Link |
---|---|
US (1) | US7220856B2 (zh) |
EP (1) | EP1534681A1 (zh) |
JP (1) | JP2005537247A (zh) |
CN (1) | CN1678586A (zh) |
AR (1) | AR040349A1 (zh) |
AU (1) | AU2003247772A1 (zh) |
BR (1) | BR0312204A (zh) |
CA (1) | CA2489560A1 (zh) |
IL (1) | IL165871A0 (zh) |
MX (1) | MXPA05000081A (zh) |
NO (1) | NO20050429L (zh) |
PE (1) | PE20040687A1 (zh) |
RU (1) | RU2005102004A (zh) |
TW (1) | TW200401774A (zh) |
UY (1) | UY27871A1 (zh) |
WO (1) | WO2004002960A1 (zh) |
ZA (1) | ZA200500790B (zh) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
MY138086A (en) * | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
US7514562B2 (en) * | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
US7666862B2 (en) * | 2003-08-15 | 2010-02-23 | Merck & Co., Inc. | Mitotic Kinesin Inhibitors |
CN102786482A (zh) | 2003-11-21 | 2012-11-21 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
AU2011265309B2 (en) * | 2003-11-21 | 2014-06-05 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
CN101090723A (zh) * | 2004-02-24 | 2007-12-19 | 舍林股份公司 | 用于治疗子宫内膜异位症的哌嗪脲衍生物 |
MXPA06011722A (es) | 2004-04-13 | 2007-01-25 | Incyte Corp | Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina. |
WO2006017326A1 (en) * | 2004-07-13 | 2006-02-16 | Glaxo Group Limited | Antibacterial agents |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US20070004763A1 (en) * | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
EP1937252B1 (en) * | 2005-09-19 | 2017-10-25 | Neuronascent, Inc. | Compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
AU2013211455B2 (en) * | 2005-09-19 | 2017-12-07 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
HUE034298T2 (en) * | 2007-05-17 | 2018-02-28 | Helperby Therapeutics Ltd | Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms |
CA2785284A1 (en) * | 2009-12-25 | 2011-06-30 | Tomoyuki Kamino | Novel aryl urea derivative |
KR20140034807A (ko) * | 2011-06-06 | 2014-03-20 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 7-클로로-4-(피페라진-1-일)-퀴놀린의 합성을 위한 신규 방법 |
BR112013032911A2 (pt) | 2011-06-19 | 2017-01-24 | Univ New York | leucotoxina e/d como um novo agente anti-inflamatório e microbicida |
EP2822936B1 (en) * | 2012-03-07 | 2021-09-08 | The McLean Hospital Corporation | Aminoquinoline derivatives and uses thereof |
WO2013192345A1 (en) | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
MX366041B (es) * | 2012-11-20 | 2019-06-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos y composiciones y método de uso de los mismos. |
WO2014134705A1 (en) * | 2013-03-04 | 2014-09-12 | Advanced Medical Research Institute Of Canada | Quinoline sulfonyl derivatives and uses thereof |
KR20170137165A (ko) | 2015-04-10 | 2017-12-12 | 베이진 엘티디 | 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘 |
CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
JP2019522627A (ja) * | 2016-05-04 | 2019-08-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
WO2017191599A1 (en) * | 2016-05-04 | 2017-11-09 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
US10414775B2 (en) * | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
US10414774B2 (en) * | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
JP2019528300A (ja) | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法 |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
PE20200296A1 (es) * | 2017-07-14 | 2020-02-06 | Innate Tumor Immunity Inc | Moduladores de nlrp3 |
JP6965432B2 (ja) * | 2017-08-29 | 2021-11-10 | チュラポーン ファンデーション | キノリンおよびナフチリジンの誘導体および組成物 |
WO2019101188A1 (en) * | 2017-11-25 | 2019-05-31 | Beigene, Ltd. | Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases |
CN111741946B (zh) * | 2017-12-29 | 2022-09-23 | 厦门宝太生物科技股份有限公司 | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 |
CN111471010B (zh) * | 2017-12-29 | 2021-09-28 | 杭州阿诺生物医药科技有限公司 | 吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法 |
PT3814347T (pt) | 2018-06-27 | 2023-07-18 | Bristol Myers Squibb Co | Compostos de naftiridinona úteis como ativadores de células t |
KR20210024586A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
WO2020233676A1 (en) * | 2019-05-22 | 2020-11-26 | Beigene, Ltd. | Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenases |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
WO2021105497A1 (en) * | 2019-11-29 | 2021-06-03 | University Of Copenhagen | Small-molecule nadph oxidase 2 inhibitors |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
CN112979546B (zh) * | 2021-02-25 | 2023-01-31 | 中国药科大学 | 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途 |
TW202304925A (zh) * | 2021-03-26 | 2023-02-01 | 美商住友製藥腫瘤公司 | (呋喃并嘧啶—4—基)哌𠯤化合物及其用途 |
WO2024017858A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel naphthyl and isoquinoline sulfonamide derivatives |
WO2024049718A2 (en) * | 2022-08-31 | 2024-03-07 | Immunocure Inc. | Quinoline piperazine derivatives, pharmaceutical composition and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR84902E (fr) * | 1962-08-30 | 1965-05-07 | Rhone Poulenc Sa | Nouveaux dérivés de la quinoléine et leur préparation |
US5494908A (en) * | 1992-11-23 | 1996-02-27 | Hoechst-Roussel Pharmaceutical Incorporated | Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds |
CN1169795C (zh) * | 1996-10-01 | 2004-10-06 | 协和发酵工业株式会社 | 环胺取代的含氮杂环化合物及其组合物 |
WO1998027815A1 (en) | 1996-12-20 | 1998-07-02 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
JP2002508366A (ja) | 1997-12-12 | 2002-03-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途 |
EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
US6344450B1 (en) | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
CN1091103C (zh) * | 1999-04-02 | 2002-09-18 | 中国科学院上海药物研究所 | 一类喹诺酮类化合物及它的制备和其用途 |
JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
WO2002072578A2 (en) | 2001-03-08 | 2002-09-19 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
-
2003
- 2003-06-24 RU RU2005102004/04A patent/RU2005102004A/ru not_active Application Discontinuation
- 2003-06-24 IL IL16587103A patent/IL165871A0/xx unknown
- 2003-06-24 EP EP03762325A patent/EP1534681A1/en not_active Withdrawn
- 2003-06-24 BR BR0312204-2A patent/BR0312204A/pt not_active IP Right Cessation
- 2003-06-24 CN CNA038204983A patent/CN1678586A/zh active Pending
- 2003-06-24 AU AU2003247772A patent/AU2003247772A1/en not_active Abandoned
- 2003-06-24 CA CA002489560A patent/CA2489560A1/en not_active Abandoned
- 2003-06-24 WO PCT/US2003/020950 patent/WO2004002960A1/en active Application Filing
- 2003-06-24 MX MXPA05000081A patent/MXPA05000081A/es unknown
- 2003-06-24 JP JP2004518228A patent/JP2005537247A/ja active Pending
- 2003-06-26 US US10/607,530 patent/US7220856B2/en not_active Expired - Fee Related
- 2003-06-27 AR ARP030102322A patent/AR040349A1/es unknown
- 2003-06-27 PE PE2003000648A patent/PE20040687A1/es not_active Application Discontinuation
- 2003-06-27 UY UY27871A patent/UY27871A1/es not_active Application Discontinuation
- 2003-06-27 TW TW092117634A patent/TW200401774A/zh unknown
-
2005
- 2005-01-26 NO NO20050429A patent/NO20050429L/no not_active Application Discontinuation
- 2005-01-26 ZA ZA200500790A patent/ZA200500790B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20040687A1 (es) | 2004-12-01 |
AR040349A1 (es) | 2005-03-30 |
MXPA05000081A (es) | 2005-04-11 |
CA2489560A1 (en) | 2004-01-08 |
UY27871A1 (es) | 2003-12-31 |
RU2005102004A (ru) | 2005-10-20 |
NO20050429D0 (no) | 2005-01-26 |
US20040072818A1 (en) | 2004-04-15 |
JP2005537247A (ja) | 2005-12-08 |
TW200401774A (en) | 2004-02-01 |
US7220856B2 (en) | 2007-05-22 |
EP1534681A1 (en) | 2005-06-01 |
WO2004002960A1 (en) | 2004-01-08 |
CN1678586A (zh) | 2005-10-05 |
AU2003247772A1 (en) | 2004-01-19 |
ZA200500790B (en) | 2006-10-25 |
IL165871A0 (en) | 2006-01-15 |
BR0312204A (pt) | 2005-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
DE60217147D1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
NO20034289L (no) | N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren | |
NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
ATE377589T1 (de) | 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten | |
NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
CA2620129C (en) | Diaminopyrimidines as p2x3 and p2x2/3 modulators | |
NO20071108L (no) | Nye 4-benzylidenpiperidinderivater | |
NO20054220L (no) | Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel | |
ATE324371T1 (de) | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten | |
SE0202465D0 (sv) | New compounds | |
NO20052474L (no) | Amort form av esomeprazolsalter | |
NO20063132L (no) | Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer | |
ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
GEP20084494B (en) | New heterocyclic carboxylic acid amide derivatives | |
NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
NO20071111L (no) | Kynurensyreamidderivater som NR2B-reseptorantagonister | |
DE60312474D1 (de) | 5-ht3-rezeptorantagonisten und verwendungsverfahren | |
NO20091052L (no) | Diaryleterderivater og anvendelser derav | |
ATE447575T1 (de) | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren | |
NO20044473L (no) | Ikke-steroidal progesteron reseptor modulatorer | |
NO20064410L (no) | Fremgangsmate for fremstilling av tryptaseinhibitorer | |
AR052931A1 (es) | Derivados de piridina sustituidos como abridores de los canales kcnq, composiciones farmaceuticas que los contienen y su uso para el tratamiento de enfermedades del snc. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |